The current state of the screening and enrollment pipeline for clinical research engagement in the era of disease modifying therapies for Alzheimer’s disease

This data suggests that increasing the pipeline of potential research participants for clinical trials should focus on continued efforts to destigmatize clinical trial engagement, adapt inclusion/exclusion criteria to allow concomitant disease-modifying therapies, and eliminate unnecessary exclusion criteria if it does not affect safety and or primary outcome measures.